Every 8-K that Rein Therapeutics, Inc. (RNTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RNTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RNTX filings page.
Rein Therapeutics, Inc. (RNTX) furnished an investor presentation highlighting its lead product candidate LTI-03, an inhaled caveolin-1 scaffolding domain peptide in development for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases. The company describes LTI-03 as a first-in-class, excipient-free dry powder therapy designed to restore caveolin-1 signaling, support alveolar epithelial cell survival, and attenuate multiple profibrotic pathways.
The presentation reports that a Phase 1b trial in IPF patients tested 5 mg and 10 mg once-daily inhaled LTI-03 over 14 days in 24 participants, met its safety and tolerability objectives with no treatment-related serious adverse events, and showed exploratory biomarker changes, including a 4.6% reduction in plasma surfactant protein D at the 10 mg dose over two weeks. Preclinical and ex vivo models demonstrate broad antifibrotic and regenerative activity in lung and other organs, and a Phase 2 RENEW trial (NCT06968845) is now enrolling. Rein also notes forward-looking risks, including the possibility that existing cash may not fund operations into the first quarter of 2028.
Rein Therapeutics, Inc. (RNTX) reported receiving a Nasdaq delisting notice on August 21, 2026, because its common stock’s closing bid price was below $1.00 per share for the prior 30 consecutive trading days, violating Nasdaq Listing Rule 5550(a)(1).
Under Nasdaq Rule 5810(c)(3)(A), Rein Therapeutics has 180 days, until February 17, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If it does not regain compliance, it may seek an additional extension period if it meets other Nasdaq Capital Market initial listing standards, but there is no assurance that extra time will be granted. Failure to regain compliance would lead Nasdaq to begin suspension and delisting procedures for the company’s common stock.
Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on July 20, 2026. Stockholders elected Class III directors Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D., with about 25.4 million votes for and 13.2 million votes withheld for each, plus 25,098,629 broker non-votes.
Stockholders approved an amendment to the restated certificate of incorporation to increase authorized common stock from 100 million shares to 200 million shares, with 61,004,221 votes for, 2,394,208 against, and 305,605 abstentions. They also ratified CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the compensation of named executive officers.
Rein Therapeutics, Inc. entered into an underwriting agreement with Konik Capital Partners for an underwritten public offering of 50,000,000 shares of common stock at $1.00 per share. This represents gross proceeds of $50 million and expected net proceeds of about $46.1 million.
The underwriter has a 45-day option to buy up to 7,500,000 additional shares. Rein issued underwriter warrants equal to 3% of the shares sold, exercisable at $1.50 per share until April 30, 2031. The company also agreed with Bios Partners to defer conversion of 12,232 preferred shares, impose a lock-up on related securities until April 30, 2029, and issue Bios warrants for 3,000,000 common shares at $1.00 per share. Rein expects the proceeds, together with existing cash, to fund operations into 2028 and fully fund its Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis.
Rein Therapeutics, Inc. entered into securities purchase agreements with three institutional investors for a private placement of unsecured promissory notes. The notes have an aggregate original principal amount of $2,875,000 and were sold for $2,300,000, reflecting a 20% original issue discount instead of cash interest.
The notes mature on the earlier of a future securities financing that brings in at least $10,000,000 of gross proceeds to the company, excluding these notes, or June 30, 2026. The obligations are unsecured, and the agreements include customary representations, warranties and covenants for this type of financing.
Rein Therapeutics, Inc. reported that Manuel C. Alves Aivado, M.D., Ph.D., has resigned from its Board of Directors, effective immediately on February 16, 2026. The company states that his resignation was not due to any disagreement with Rein on its operations, policies, or practices.
The filing confirms Rein Therapeutics remains listed on the Nasdaq Capital Market under the symbol RNTX, and is signed by President and Chief Executive Officer Brian Windsor, Ph.D.
Rein Therapeutics, Inc. entered into a securities purchase agreement with Funicular Funds, LP under which it issued an unsecured promissory note with an original principal amount of $2,500,000 in a private placement. Funicular paid a purchase price of $2,000,000, reflecting a 20% original issue discount instead of cash interest. The note matures on the earlier of the closing of the Company’s next securities financing that raises at least $10,000,000 in gross proceeds (excluding this note) or June 30, 2026. The obligations are unsecured, and the agreement includes customary representations, warranties, covenants and other terms. The note was sold as a private offering under Section 4(a)(2) and Rule 506 of Regulation D.
Rein Therapeutics, Inc. elected to terminate its Pre-Paid Advance Agreement and its Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) on December 11, 2025.
Under the Pre-Paid Advance Agreement, the company had received advances totaling $3 million, with the most recent advance taken on October 23, 2025. The company conducted no sales of its common stock under the Standby Equity Purchase Agreement before termination and reports that no penalties or fees were incurred in connection with ending either arrangement.
Rein Therapeutics announced FDA clearance to resume its U.S. Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis. The company disclosed the update via a press release furnished as Exhibit 99.1 to this report. No financial terms or operational details were provided in this excerpt.
Rein Therapeutics (RNTX) entered a third Pre-Paid Advance with Yorkville. On October 23, 2025, the company drew a $1.0 million Pre-Paid Advance, receiving net proceeds of $0.95 million. Under the existing agreement, advances are purchased at 95% of face value, accrue interest at 8% annually (rising to 18% upon certain defaults), and mature 12 months after issuance.
The PPA permits Yorkville to require the company to issue common stock to offset outstanding balances. Earlier tranches included a $1.0 million First Advance on July 29, 2025 and a $1.0 million Second Advance on September 8, 2025, each providing $0.95 million in net proceeds. As of this report, the company issued 953,765 shares at an average price of approximately $1.0562 to offset $1,007,342 under the First Advance, and 927,107 shares at an average price of approximately $1.0825 to offset $1,003,573 under the Second Advance. The third advance was completed as a private placement relying on Section 4(a)(2).
Rein Therapeutics, Inc. furnished a current report on Form 8-K noting that the company issued a press release dated October 9, 2025. The filing indicates the press release was provided as an interactive data file within the Inline XBRL document and is signed by Brian Windsor, Ph.D., Chief Executive Officer.
No financial results, transactions, corporate developments, or other substantive disclosures are included in the text provided here; the filing appears limited to furnishing the press release.
Rein Therapeutics (RNTX) reports that the RENEW Phase 2 clinical trial is subject to a clinical hold, creating uncertainty about timing and the studies or actions needed to resolve the hold. The company warns that delays could strain its cash resources and affect its ability to fund the trial and operations through completion. It also notes the risk that early-stage results may not be replicated later, potential difficulties enrolling patients, and challenges integrating Qureight's deep-learning platform into the trial. The filing points readers to the company’s 2024 Form 10-K for additional risk factors and reiterates standard forward-looking statement disclaimers.
Rein Therapeutics, Inc. (RNTX) entered a Pre-Paid Advance Agreement with YA II PN, Ltd. (Yorkville) allowing up to $6.0 million of prepaid advances over 12 months, each purchased at 95% of face value and due 12 months after issuance. Interest on outstanding advances accrues at 8% annually, rising to 18% upon certain defaults. An initial $1.0 million advance was purchased on the effective date for net proceeds of $0.95 million. The company issued 479,036 shares of common stock (average price ~$1.06 per share) to Yorkville, which were applied against $500,000 of the initial advance. The placement was done in a private transaction relying on Section 4(a)(2) of the Securities Act with no underwriter.
Rein Therapeutics, Inc. reported that it issued a press release about the planned Phase 2 clinical trial of its LTI-03 product candidate in the U.K. The company used this report to formally note the communication to the market and attached the press release as an exhibit for investors to review.
The filing does not provide clinical, financial, or operational details about the Phase 2 trial itself, but directs readers to the full press release, dated August 19, 2025, for more information on the LTI-03 development plans.
On 29 Jul 2025 Rein Therapeutics (RNTX) entered two financing arrangements with YA II PN, Ltd. 1) Pre-Paid Advance Agreement (PPA): the company can draw up to $6.0 m over 12 months; Yorkville purchases each advance at 95% of face value (initial draw $1.0 m yielded $0.95 m). Interest accrues at 8% (18% upon default). Yorkville may force repayment in shares at the lower of 115% of prior-day VWAP or 95% of the lowest VWAP in the prior 7 trading days, but not below a $0.28 floor. Floor-price, registration-effectiveness or exchange-cap breaches trigger monthly cash amortization of up to 25% of the original advance.
2) Standby Equity Purchase Agreement (SEPA): provides an equity line of up to $15.0 m over 36 months. Each advance is priced at 96% of the lowest VWAP during the three days after an advance notice, subject to volume and minimum-price limits. Rein paid a $300 k commitment fee via 213,099 shares and $25 k expenses.
The aggregate shares issuable under both facilities are capped at 19.9% of current outstanding stock, and Yorkville’s ownership is limited to 4.99%. PPA shares will be issued off the company’s shelf registration; SEPA shares require an effective resale registration statement. The facilities give Rein up to ~$21 m in gross liquidity with flexible timing, but at the cost of discounted pricing, possible dilution and potential downward pressure on the share price.
Rein Therapeutics (NASDAQ: RNTX) announced the adjournment of its 2025 Annual Meeting of Stockholders originally scheduled for June 24, 2025. The meeting has been rescheduled to July 23, 2025 due to failure to achieve a quorum.
Key details of the adjournment:
- Original meeting date: June 24, 2025
- New meeting date: July 23, 2025
- Record date remains: May 5, 2025
- Purpose: To allow additional time for stockholders to vote on proposals outlined in the proxy statement filed May 12, 2025
The Form 8-K was filed by President and CEO Brian Windsor, Ph.D. from the company's Austin, Texas headquarters. This development indicates potential challenges in securing sufficient shareholder participation for important corporate governance matters.